HIV infection and risk of overdose: A systematic review and meta-analysis

AIDS

Volumn 26, Issue 4, 2012, Pages 403-417

  Green, Traci C ^a,b,c   McGowan, Samuel K ^d   Yokell, Michael A ^a,d,e   Pouget, Enrique R ^f   Rich, Josiah D ^a,b,d  

^a BROWN UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

^c RHODE ISLAND HOSPITAL   (United States)

^d MIRIAM HOSPITAL   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

Author keywords

fatal; HIV; mortality; opioid; overdose

Indexed keywords

ANTIRETROVIRUS AGENT; NALOXONE;

CAUSE OF DEATH; COHORT ANALYSIS; DRUG FATALITY; DRUG MECHANISM; DRUG OVERDOSE; EMERGENCY WARD; FOLLOW UP; HEPATITIS B; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; META ANALYSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; REVIEW; SUBSTANCE ABUSE; TREATMENT OUTCOME;

ANALGESICS, OPIOID; FEMALE; HIV SEROPOSITIVITY; HUMANS; MALE; OVERDOSE; RISK ASSESSMENT; RISK FACTORS; SOCIOECONOMIC FACTORS; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84857045428     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834f19b6     Document Type: Review

References (110)

1. Eskild A, Magnus P, Samuelsen SO, Sohlberg C, Kittelsen P. Differences in mortality rates and causes of death between HIV positive and HIV negative intravenous drug users. Int J Epidemiol 1993; 22:315-320. (Pubitemid 23129336)
2. Ferreros I, Lumbreras B, Hurtado I, Pérez-Hoyos S, Hernández-Aguado I. The shifting pattern of cause-specific mortality in a cohort of human immunodeficiency virus-infected and noninfected injecting drug users. Addiction 2008; 103:651-659. (Pubitemid 351389277)
3. Penning R, Fromm E, Betz P, Kauert G, Drasch G, von Meyer L. Drug death autopsies at the Munich Institute of Forensic Medicine (1981-1992). Forensic Sci Int 1993; 62:135-139. (Pubitemid 23346541)
4. Seaman SR, Brettle RP, Gore SM. Mortality from overdose among injecting drug users recently released from prison: database linkage study. BMJ 1998; 316:426-428. (Pubitemid 28121295)
5. EMCDDA. Annual report on the state of drugs problem in Europe. Lisbon, Portugal: European Monitoring Centre for Drugs and Drug Addiction; 2010.
6. Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med 2006; 145:397-406. (Pubitemid 46768570)
7. The U.S. President's Emergency Plan for AIDS Relief (PEPFAR). Comprehensive HIV prevention for people who inject drugs, revised guidance. Washington, District of Columbia: Office of the Global AIDS Coordinator; 2010. p. 13. http://www.pepfar.gov/guidance/idu/. [Accessed 5 August 2011]
8. The Global Fund to Fight AIDS Tuberculosis and Malaria. Harm reduction for people who use drugs: information note. Geneva, Switzerland: The Global Fund; 2011. p. 6.
9. World Health Organization. Opiates: facts and figures. Geneva, Switzerland: WHO Press; 2011. http://www.who. int/substance-abuse/facts/opiates/ en/. [Accessed 4 August 2011]
10. United Nations Office on Drugs and Crime. World drug report 2009. Vienna, Austria: United Nations Office on Drugs and Crime; 2009.
11. World Health Organization, UNAIDS Joint United Nations Program on HIV/AIDS. HIV prevention among injecting drug users. Paper to the 24th Meeting of the UNAIDS Programme Coordinating Board; Geneva, Switzerland: UNAIDS. June 2009. p. 25. http://data.unaids.org/pub/InformationNote/2009/20090518-hiv- prevention-among-idus-final-en.pdf. [Accessed 5 August 2011]
12. Hickman M, Hope V, Coleman B, Parry J, Telfer M, Twigger J, et al. Assessing IDU prevalence and health consequences (HCV, overdose and drug-related mortality) in a primary care trust: implications for public health action. J Public Health (Oxf) 2009; 31:374-382.
13. Solomon SS, Celentano DD, Srikrishnan AK, Vasudevan CK, Anand S, Kumar MS, et al. Mortality among injection drug users in Chennai, India (2005-2008). AIDS 2009; 23:997-1004.
14. Darke S, Zador D. Fatal heroin 'overdose': a review. Addiction 1996; 91:1765-1772. (Pubitemid 27032489)
15. Seal KH, Kral AH, Gee L, Moore LD, Bluthenthal RN, Lorvick J, et al. Predictors and prevention of nonfatal overdose among street-recruited injection heroin users in the San Francisco Bay Area, 1998-1999. Am J Public Health 2001; 91:1842-1846. (Pubitemid 33031743)
16. Sherman SG, Cheng Y, Kral AH. Prevalence and correlates of opiate overdose among young injection drug users in a large U.S. city. Drug Alcohol Depend 2007; 88:182-187. (Pubitemid 46482817)
17. Pollini RA, McCall L, Mehta SH, Vlahov D, Strathdee SA. Nonfatal overdose and subsequent drug treatment among injection drug users. Drug Alcohol Depend 2006; 83:104-110. (Pubitemid 43795468)
18. Havens JR, Oser CB, Knudsen HK, Lofwall M, Stoops WW, Walsh SL, et al. Individual and network factors associated with nonfatal overdose among rural Appalachian drug users. Drug Alcohol Depend 2011; 115:107-112.
19. Green TC, Grimes Serrano JM, Licari A, Budman SH, Butler SF. Women who abuse prescription opioids: findings from the Addiction Severity Index-Multimedia Version Connect prescription opioid database. Drug Alcohol Depend 2009; 103:65-73.
20. Warner-Smith M, Darke S, Lynskey M, Hall W. Heroin overdose: causes and consequences. Addiction 2001; 96:1113-1125. (Pubitemid 32738391)
21. Green TC, Grau LE, Blinnikova KN, Torban M, Krupitsky E, Ilyuk R, et al. Social and structural aspects of the overdose risk environment in St. Petersburg, Russia. Int J Drug Policy 2009; 20:270-276.
22. Piper T, Rudenstine S, Stancliff S, Sherman S, Nandi V, Clear A, et al. Overdose prevention for injection drug users: lessons learned from naloxone training and distribution programs in New York City. Harm Reduct J 2007; 4:3.
23. Goedert JJ, Fung MW, Felton S, Battjes RJ, Engels EA. Causespecific mortality associated with HIV and HTLV-II infections among injecting drug users in the USA. AIDS 2001; 15:1295-1302. (Pubitemid 32592363)
24. Brettle RP, Chiswick A, Bell J, Busuttil A, Wilson A, Povey S, et al. Pre-AIDS deaths in HIV infection related to intravenous drug use. QJM 1997; 90:617-629. (Pubitemid 27453826)
25. Wang C, Vlahov D, Galai N, Cole SR, Bareta J, Pollini R, et al. The effect of HIV infection on overdose mortality. AIDS 2005; 19:935-942. (Pubitemid 40834936)
26. Brugal MT, Barrio G, DeLa Fuente F, Regidor E, Royuela L, Suelves JM. Factors associated with nonfatal heroin overdose: assessing the effect of frequency and route of heroin administration. Addiction 2002; 97:319-327. (Pubitemid 34250729)
27. Fingerhood M, Rastegar DA, Jasinski D. Five year outcomes of a cohort of HIV-infected injection drug users in a primary care practice. J Addict Dis 2006; 25:33-38. (Pubitemid 44157066)
28. Lyles CM, Margolick JB, Astemborski J, Graham NM, Anthony JC, Hoover DR, et al. The influence of drug use patterns on the rate of CD4R lymphocyte decline among HIV-1-infected injecting drug users. AIDS 1997; 11:1255-1262. (Pubitemid 27298092)
29. Goedert JJ, Pizza G, Gritti FM, Costigliola P, Boschini A, Bini A, et al. Mortality among drug users in the AIDS era. Int J Epidemiol 1995; 24:1204-1210. (Pubitemid 26025033)
30. Van Ameijden EJ, Langendam MW, Coutinho RA. Dose-effect relationship between overdose mortality and prescribed methadone dosage in low-threshold maintenance programs. Addict Behav 1999; 24:559-563. (Pubitemid 29342933)
31. Rhodes T. Risk environments and drug harms: a social science for harm reduction approach. Int J Drug Policy 2009; 20:193-201.
32. Rhodes T, Kimber J, Small W, Fitzgerald J, Kerr T, Hickman M, et al. Public injecting and the need for 'safer environment interventions' in the reduction of drug-related harm. Addiction 2006; 101:1384-1393. (Pubitemid 44337759)
33. Rhodes T, Singer M, Bourgois P, Friedman SR, Strathdee SA. The social structural production of HIV risk among injecting drug users. Soc Sci Med 2005; 61:1026-1044. (Pubitemid 40805548)
34. Marshall BD, Kerr T, Qi J, Montaner JS, Wood E. Public injecting and HIV risk behaviour among street-involved youth. Drug Alcohol Depend 2010; 110:254-258.
35. Kerr T, Small W, Moore D, Wood E. A micro-environmental intervention to reduce the harms associated with drugrelated overdose: evidence from the evaluation of Vancouver's safer injection facility. Int J Drug Policy 2007; 18:37-45. (Pubitemid 46240802)
36. Marshall BD, Milloy MJ, Wood E, Montaner JS, Kerr T. Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study. Lancet 2011; 377:1429-1437.
37. Haddon W Jr. On the escape of tigers: an ecologic note. Am J Public Health 1970; 60:2229-2234.
38. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21:1539-1558. (Pubitemid 34746062)
39. Borenstein M, Hedges L, Rothstein H. Comprehensive metaanalysis. Englewood, New Jersey: Biostat; 2005.
40. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188. (Pubitemid 17189972)
41. Sterne JA, Egger M. Funnel plots for detecting bias in metaanalysis: guidelines on choice of axis. J Clin Epidemiol 2001; 54:1046-1055. (Pubitemid 32888370)
42. Brugal MT, Domingo-Salvany A, Puig R, Barrio G, Garc?́a de Olalla P, de la Fuente L. Evaluating the impact of methadone maintenance programmes on mortality due to overdose and aids in a cohort of heroin users in Spain. Addiction 2005; 100:981-989. (Pubitemid 40897293)
43. Ochoa KC, Davidson PJ, Evans JL, Hahn JA, Page-Shafer K, Moss AR. Heroin overdose among young injection drug users in San Francisco. Drug Alcohol Depend 2005; 80:297-302. (Pubitemid 41660850)
44. Quaglio G, Talamini G, Lechi A, Venturini L, Lugoboni F, Mezzelani P, et al. Study of 2708 heroin-related deaths in north-eastern Italy 1985-98 to establish the main causes of death. Addiction 2001; 96:1127-1137. (Pubitemid 32738392)
45. Tardiff K, Marzuk PM, Leon AC, Hirsch CS, Portera L, Hartwell N. HIV infection among victims of accidental fatal drug overdoses in New York City. Addiction 1997; 92:1017-1022. (Pubitemid 27359411)
46. Vlahov D, Tang AM, Lyles C, Rezza G, Thomas D, Cohn S, et al. Increased frequency of overdose deaths among HIVinfected injection drug users. Addict Res 2000; 8:311-326.
47. Zaccarelli M, Gattari P, Rezza G, Conti S, Spizzichino L, Vlahov D, et al. Impact of HIV infection on non-AIDS mortality among Italian injecting drug users. AIDS 1994; 8:345-350. (Pubitemid 24094143)
48. Cattaneo C, Nuttall PA, Molendini LO, Pellegrinelli M, Grandi M, Sokol RJ. Prevalence of HIV and hepatitis C markers among a cadaver population in Milan. J Clin Pathol 1999; 52:267-270. (Pubitemid 29161488)
49. Cohen MH, French AL, Benning L, Kovacs A, Anastos K, Young M, et al. Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. Am J Med 2002; 113:91-98. (Pubitemid 34804744)
50. Kohli R, Lo Y, Howard AA, Buono D, Floris-Moore M, Klein RS, et al. Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 41:864-872. (Pubitemid 41266755)
51. Langendam MW, van Brussel GH, Coutinho RA, van Ameijden EJ. The impact of harm-reduction-based methadone treatment on mortality among heroin users. Am J Public Health 2001; 91:774-780. (Pubitemid 32397914)
52. Manfredi R, Sabbatani S, Agostini D. Trend of mortality observed in a cohort of drug addicts of the metropolitan area of Bologna, North-Eastern Italy, during a 25-year-period. Coll Antropol 2006; 30:479-488. (Pubitemid 44519493)
53. Muga R, Roca J, Egea JM, Tor J, Sirera G, Rey-Joly C, et al. Mortality of HIV-positive and HIV-negative heroin abusers as a function of duration of injecting drug use. J Acquir Immune Defic Syndr 2000; 23:332-338. (Pubitemid 30327036)
54. Palepu A, Khan NA, Norena M, Wong H, Chittock DR, Dodek PM. The role of HIV infection and drug and alcohol dependence in hospital mortality among critically ill patients. J Crit Care 2008; 23:275-280.
55. Scheer S, McQuitty M, Denning P, Hormel L, Stephens B, Katz M, et al. Undiagnosed and unreported AIDS deaths: results from the San Francisco Medical Examiner. J Acquir Immune Defic Syndr 2001; 27:467-471. (Pubitemid 32801076)
56. Smith DK, Gardner LI, Phelps R, Hamburger ME, Carpenter C, Klein RS, et al. Mortality rates and causes of death in a cohort of HIV-infected and uninfected women, 1993-1999. J Urban Health 2003; 80:676-688. (Pubitemid 38146231)
57. Tyndall MW, Craib KJ, Currie S, Li K, O'Shaughnessy MV, Schechter MT. Impact of HIV infection on mortality in a cohort of injection drug users. J Acquir Immune Defic Syndr 2001; 28:351-357. (Pubitemid 33101288)
58. van Haastrecht HJ, van Ameijden EJ, van den Hoek JA, Mientjes GH, Bax JS, Coutinho RA. Predictors of mortality in the Amsterdam cohort of human immunodeficiency virus (HIV)-positive and HIV-negative drug users. Am J Epidemiol 1996; 143:380-391. (Pubitemid 26055126)
59. van Haastrecht HJ, Mientjes GH, van den Hoek AJ, Coutinho RA. Death from suicide and overdose among drug injectors after disclosure of first HIV test result. AIDS 1994; 8:1721-1725. (Pubitemid 24357849)
60. Stoneburner RL, Des Jarlais DC, Benezra D, Gorelkin L, Sotheran JL, Friedman SR, et al. A larger spectrum of severe HIV-1: related disease in intravenous drug users in New York City. Science 1988; 242:916-919. (Pubitemid 19015252)
61. De Palo VA, Millstein BH, Mayo PH, Salzman SH, Rosen MJ. Outcome of intensive care in patients with HIV infection. Chest 1995; 107:506-510.
62. Prins M, Hernández Aguado IH, Brettle RP, Robertson JR, Broers B, Carré N, et al. Pre-AIDS mortality from natural causes associated with HIV disease progression: evidence from the European Seroconverter Study among injecting drug users. AIDS 1997; 11:1747-1756. (Pubitemid 27470277)
63. Neira-León M, Barrio G, Bravo MJ, Brugal MT, de la Fuente L, Domingo-Salvany A, et al. Infrequent opioid overdose risk reduction behaviours among young adult heroin users in cities with wide coverage of HIV prevention programmes. Int J Drug Policy 2011; 22:16-25.
64. Bargagli AM, Schifano P, Davoli M, Faggiano F, Perucci CA, Group VS. Determinants of methadone treatment assignment among heroin addicts on first admission to public treatment centres in Italy. Drug Alcohol Depend 2005; 79:191-199. (Pubitemid 40942109)
65. Carvajal MJ, Vicioso C, Santamaria JM, Bosco A. AIDS and suicide issues in Spain. AIDS Care 1995; 7 (Suppl 2):S135-S138. (Pubitemid 26004529)
66. Eskild A, Magnus P, Sohlberg C, Kittelsen P, Olving JH, Teige B, et al. Slow progression to AIDS in intravenous drug users infected with HIV in Norway. J Epidemiol Community Health 1994; 48:383-387. (Pubitemid 24271310)
67. Krentz HB, Kliewer G, Gill MJ. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. HIV Med 2005; 6:99-106. (Pubitemid 40425973)
68. Laurichesse HA, Mortimer J, Evans BG, Farrington CP. Pre-AIDS mortality in HIV-infected individuals in England, Wales and Northern Ireland, 1982-1996. AIDS 1998; 12:651-658. (Pubitemid 28162105)
69. Mezzelani P, Quaglio GL, Venturini L, Lugoboni F, Friedman SR, Des Jarlais DC. A multicentre study on the causes of death among Italian injecting drug users. AIDS has overtaken overdose as the principal cause of death. AIDS Care 1998; 10:61-67.
70. Miller CL, Kerr T, Strathdee SA, Li K, Wood E. Factors associated with premature mortality among young injection drug users in Vancouver. Harm Reduct J 2007; 4:1.
71. Mirakbari SM, Innes GD, Christenson J, Tilley J, Wong H. Do co-intoxicants increase adverse event rates in the first 24 h in patients resuscitated from acute opioid overdose?. J Toxicol Clin Toxicol 2003; 41:947-953. (Pubitemid 38018485)
72. Selwyn PA, Alcabes P, Hartel D, Buono D, Schoenbaum EE, Klein RS, et al. Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. N Engl J Med 1992; 327:1697-1703.
73. Talaie H, Shadnia SH, Okazi A, Pajouhmand A, Hasanian H, Arianpoor H. The prevalence of hepatitis B, hepatitis C and HIV infections in non-IV drug opioid poisoned patients in Tehran-Iran. Pak J Biol Sci 2007; 10:220-224. (Pubitemid 46197768)
74. van Asten L, Zangerle R, Hernández Aguado I, Boufassa F, Broers B, Brettle RP, et al. Do HIV disease progression and HAART response vary among injecting drug users in Europe? Eur J Epidemiol 2005; 20:795-804. (Pubitemid 41374305)
75. Aidala A, Cross JE, Stall R, Harre D, Sumartojo E. Housing status and HIV risk behaviors: implications for prevention and policy. AIDS Behav 2005; 9:251-265. (Pubitemid 41584978)
76. Seaman SR, Brettle RP, Gore SM. Pre-AIDS mortality in the Edinburgh City Hospital HIV cohort. Stat Med 1997; 16:2459-2474. (Pubitemid 27472718)
77. Gruber VA, McCance-Katz EF. Methadone, buprenorphine, and street drug interactions with antiretroviral medications. Curr HIV/AIDS Rep 2010; 7:152-160.
78. Bruce RD, Kresina TF, McCance-Katz EF. Medication-assisted treatment and HIV/AIDS: aspects in treating HIV-infected drug users. AIDS 2010; 24:331-340.
79. Bruce RD, Altice FL, Gourevitch MN, Friedland GH. Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J Acquir Immune Defic Syndr 2006; 41:563-572.
80. Bruce RD, McCance-Katz E, Kharasch ED, Moody DE, Morse GD. Pharmacokinetic interactions between buprenorphine and antiretroviral medications. Clin Infect Dis 2006; 43 (Suppl 4):S216-S223. (Pubitemid 44901889)
81. Bruce RD. Methadone as HIV prevention: high volume methadone sites to decrease HIV incidence rates in resource limited settings. Int J Drug Policy 2010; 21:122-124.
82. Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor R, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess 2007; 11:1-171.
83. Keen J, Rowse G, Mathers N, Campbell M, Seivewright N. Can methadone maintenance for heroin-dependent patients retained in general practice reduce criminal conviction rates and time spent in prison? Br J Gen Pract 2000; 50:48-49. (Pubitemid 30026005)
84. Kinlock TW, Gordon MS, Schwartz RP, Fitzgerald TT, O'Grady KE. A randomized clinical trial of methadone maintenance for prisoners: results at 12 months postrelease. J Subst Abuse Treat 2009; 37:277-285.
85. Mattick RP, Ali R, White JM, O'Brien S, Wolk S, Danz C. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction 2003; 98:441-452. (Pubitemid 36458126)
86. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009: CD002209.
87. Moatti JP, Carrieri MP, Spire B, Gastaut JA, Cassuto JP, Moreau J. Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group. AIDS 2000; 14:151-155. (Pubitemid 30116440)
88. Roux P, Carrieri MP, Villes V, Dellamonica P, Poizot-Martin I, Ravaux I, et al. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study. Addiction 2008; 103:1828-1836.
89. Springer SA, Chen S, Altice FL. Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment. J Urban Health 2010; 87:592-602.
90. Metzger D, Woody G, O'Brian C. Drug Treatment as HIV prevention: a research update. J Acquir Immune Defic Syndr 2010; 55:s32-s36.
91. Gowing LR, Farrell M, Bornemann R, Sullivan LE, Ali RL. Brief report: methadone treatment of injecting opioid users for prevention of HIV infection. J Gen Intern Med 2006; 21:193-195. (Pubitemid 43363679)
92. Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 2010; 375:1014-1028.
93. Davoli M, Bargagli AM, Perucci CA, Schifano P, Belleudi V, Hickman M, et al. Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multisite prospective cohort study.Addiction 2007; 102:1954-1959. (Pubitemid 350145672)
94. Sporer KA. Acute heroin overdose. Ann Intern Med 1999; 130:584-590. (Pubitemid 29169387)
95. Sporer KA, Kral AH. Prescription naloxone: a novel approach to heroin overdose prevention. Ann Emerg Med 2007; 49:172-177. (Pubitemid 46127584)
96. Seal KH, Thawley R, Gee L, Bamberger J, Kral AH, Ciccarone D, et al. Naloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention study. J Urban Health 2005; 82:303-311. (Pubitemid 41214946)
97. Maxwell S, Bigg D, Stanczykiewicz K, Carlberg-Racich S. Prescribing naloxone to actively injecting heroin users: a program to reduce heroin overdose deaths. J Addict Dis 2006; 25:89-96. (Pubitemid 44352907)
98. Galea S, Worthington N, Piper TM, Nandi VV, Curtis M, RosenthalDM. Provision of naloxone to injection drug users as an overdose prevention strategy: early evidence froma pilot study in New York City. Addict Behav 2006; 31:907-912.
99. Doe-Simkins M, Walley AY, Epstein A, Moyer P. Saved by the nose: bystander-administered intranasal naloxone hydrochloride for opioid overdose. Am J Public Health 2009; 99:788-791.
100. Sherman SG, Gann DS, Tobin KE, Latkin CA, Welsh C, Bielenson P. The life they save may be mine': diffusion of overdose prevention information from a city sponsored programme. Int J Drug Policy 2009; 20:137-142.
101. Yokell M, Green TC, Bowman S, McKenzie M, Rich J. opioid overdose prevention and naloxone distribution in Rhode Island. Med Health Rhode Island 2011; 94:240-242.
102. Walley AY. Implementation and evaluation of Massachusetts' overdose education and naloxone distribution program. In: American Public Health Association Annual Conference; 2011; Washington, DC, USA.
103. Walley AY, Xuan Z, Hackman H, Ozonoff A, Quinn E, Pierce C, et al. Is implementation of bystander overdose education and naloxone distribution associated with lower opioidrelated overdose rates in Massachusetts? In: Association of Medical Education and Research on Substance Abuse; 2011; Arlington, VA, USA.
104. World Health Organization. WHO model list of essential medicines, 17th list. Geneva, Switzerland: WHO Press; 2011. pp. 1-45.
105. World Health Organization. International statistical classification of diseases and related health problems: tenth revision (ICD-10), 2nd ed.Geneva, Switzerland:WHOPress; 1994.
106. Pouget ER, Kershaw TS, Niccolai LM, Ickovics JR, Blankenship KM. Associations of sex ratios and male incarceration rates with multiple opposite-sex partners: potential social determinants of HIV/STI transmission. Public Health Rep 2010; 125 (Suppl 4):70-80.
107. Blankenship KM, Smoyer AB, Bray SJ, Mattocks K. Black-white disparities in HIV/AIDS: the role of drug policy and the corrections system. J Health Care Poor Underserved 2005; 16:140-156. (Pubitemid 41812986)
108. Blankenship KM, Bray SJ, Merson MH. Structural interventions in public health. AIDS 2000; 14 (Suppl 1):S11-S21.
109. Vaca FE, Kohl V. Pediatric pedestrian injury. Top Emerg Med 2006; 28:30-38. (Pubitemid 44145664)
110. Vaca FE, Anderson CL, Herrera H, Patel C, Silman EF, Deguzman R, et al. Crash injury prediction and vehicle damage reporting by paramedics. West J Emerg Med 2009; 10:62-67.